Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10134740 | 0.87 | HPGD (0.49) | PDE2ACASP1HTTKMT2AALDH1A1 | |
| SCHEMBL10134750 | 0.85 | HCRTR1 (0.50) | CASP1TP53HTTKMT2AALDH1A1 | |
| SCHEMBL12359369 | 0.82 | CYP2A6 (0.47) | PDE2ATP53MKNK1MKNK2HTT | |
| SCHEMBL12024774 | 0.82 | PDE2A (0.49) | PDE2AMKNK1MKNK2 | |
| SCHEMBL12391556 | 0.81 | CYP2A6 (0.48) | PDE2AMKNK1MKNK2HTTKMT2A | |
| SCHEMBL10134760 | 0.79 | PDE2A (0.46) | PDE2AMKNK1MKNK2 | |
| SCHEMBL12391550 | 0.78 | MKNK1 (0.54) | PDE2AMKNK1MKNK2 | |
| SCHEMBL12359372 | 0.78 | HTT (0.53) | TP53HTTKMT2AALDH1A1CYP2C9 | |
| SCHEMBL16435360 | 0.77 | ALDH1A1 (0.50) | PDE2ACASP1TP53HTTALDH1A1 | |
| SCHEMBL12359373 | 0.77 | POLQ (0.47) | PDE2AMKNK1MKNK2HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703770-B2 | Pyridazine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120046289-A1 | Pyridazine Carboxamide Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046289-A1 | Pyridazine Carboxamide Orexin Receptor Antagonists | HCRTR2, HCRTR1, NPY5R | PDE2A 2326/4885CASP1 2747/4885TP53 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.